S&P Futures
2,423.50
+3.00 (+0.12%)Dow Futures
21,310.00
+19.00 (+0.09%)
| Previous Close | 3.40 |
| Open | 3.41 |
| Bid | 3.42 x 3000 |
| Ask | 3.45 x 4700 |
| Day's Range | 3.39 - 3.44 |
| 52 Week Range | 0.32 - 6.48 |
| Volume | 38,044 |
| Avg. Volume | 94,846 |
| Market Cap | 146.19M |
| Beta | 0.61 |
| PE Ratio (TTM) | -1.27 |
| EPS (TTM) | -2.69 |
| Earnings Date | Aug 2, 2017 - Aug 7, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
- PR Newswire•13 days ago
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE , June 15, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to ...
- Capital Cube•20 days ago
ETFs with exposure to CTI BioPharma Corp. : June 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•22 days ago
CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
SEATTLE, June 6, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the "Offering"). Each share of Series N-3 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $3.00 per share of common stock, for a total of approximately 15.0 million shares of common stock.